Insider Transaction Report for Avalo Therapeutics, Inc.

This filing details a transaction by Gilla Kaplan, a director at Avalo Therapeutics, Inc., on March 28, 2026. The transaction involved 3,166 shares of Common Stock acquired under transaction code "M" with a price of $0.00 per share, resulting in 6,333 shares held post-transaction. Additionally, 3,166 Restricted Stock Units were disposed of under transaction code "M", converting into Common Stock on a one-for-one basis as per footnote F1. These RSUs were granted on August 13, 2024, with a vesting schedule of one-third on March 28, 2025, 2026, and 2027, contingent upon continued service, as noted in footnote F2. The post-transaction shares for RSUs amounted to 3,167.